Larazotide

Larazotide is a synthetic 8‑amino‑acid peptide that modulates intestinal tight junctions and is chiefly used off‑label to improve gut permeability or “leaky gut.” Community users typically take 500 µg daily, with doses ranging from 150 µg to 500 µg, administered each day without a set cycle. About 15 % of participants in the registered trial program dropped out, occasional reports note mild edema, injection‑site reactions and other common side effects have not been observed, and there is no FDA‑approved indication, so all human use is off‑label.

Half-life~30 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice3.41.72.53.22.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Larazotide possesses low-tier clinical evidence, primarily consisting of exploratory human studies focused on Celiac disease and Fabry disease. While 13 trials have been registered across seven distinct indications, the research remains thin, with most areas supported by only single-trial data or early-stage investigations. The quality of evidence is limited by a reliance on Phase 2 data and a 15% withdrawal rate across three distinct sponsors, signaling that despite a decade of registered activity, the peptide lacks the robust, large-scale validation required to establish consistent clinical efficacy.

Depthhow much
13 registered trials
11 completed
Breadthhow many areas
7 indications mapped
5 thin / exploratory · 1 animal-only · 3 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 2
3 distinct sponsors · 15% withdrawal rate · 4 linked publications on registered trials
Breadth and depth37 rows captured
Human
direct clinical signal
19
Animal
translational support
12
In vitro
mechanistic support
6
HighMediumLow

Anecdotal efficacy

Larazotide side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

Full buying guide →
1
Rp Peptides
GB
15 mg×60
$30.20
$2.01/mg
2
Peptides.co.za
South Africa
50 mg
ZAR 2000.00
ZAR 40.00/mg
3
Biolab Peptides
GB
0.25 mg×60
$87.25
$348.99/mg

price offers can be sorted by column · 3 out-of-stock offers not shown

Larazotide dosing & protocol

How Larazotide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 10
Typical dose
1 mg250 µg – 8 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 7 reported doses · darker = more
Frequency
three times daily
Route
oral

In research trials, larazotide was given orally at doses ranging from 250 µg to 8 mg, most commonly 1 mg three times daily. No cycling regimen was reported.

10 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 4
Typical dose
500 µg150 µg – 500 µg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 4 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
oral

Most users take it daily, typically 500 µg, with reported doses ranging from 150 µg to 500 µg; one contributor listed a dose without specifying a schedule.

4 sources